Seer Appoints Meeta Gulyani to its Board of Directors

Rhea-AI Summary

Seer, Inc. (Nasdaq: SEER) has appointed Meeta Gulyani to its Board of Directors. Gulyani, currently Executive Vice President at Merck KGaA, brings extensive experience in life sciences. Her leadership is expected to support Seer's mission in proteomics, which aims to unlock new insights in healthcare. Gulyani has held significant roles at Roche and possesses a strong background in strategy, business development, and transformation. Seer's Proteograph Product Suite is at the forefront of proteomic analysis, enhancing research capabilities in various laboratories.

Positive

• Meeta Gulyani brings extensive experience in life sciences and global markets, which could enhance Seer's strategic capabilities.
• Her leadership is expected to accelerate Seer's mission in revolutionizing proteomics.

Negative

• None.

REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada.

“Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Meeta to our Board,” said Omid Farokhzad, M.D., Chair, Chief Executive Officer and Founder of Seer. “Meeta’s experience, expertise and passion for innovation in healthcare will be an asset to the Seer Board and accelerating our mission of opening up a new gateway to the proteome.”

“I am honored to join the Seer Board and excited to contribute to the company’s mission,” said Ms. Gulyani. “Seer is redefining what’s possible in proteomics, creating a path to drive new insights and revolutionize our understanding of biology – it truly is the next frontier in human health. I look forward to partnering with the Seer team to accelerate this incredible transformation."

In her current role as Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, Meeta leads the development of the Life Science sector strategy and searches out and delivers deals of value to enable the achievement of its growth ambition. Meeta was previously Executive Vice President and Head of Strategy and Global Franchises for the Biopharma business of Merck KGaA, Darmstadt, Germany. Prior to that, she served as General Manager for Roche South Asia, and Vice President, Head of Global Portfolio Management at Roche. Prior to Roche, Meeta held several marketing and sales leadership positions within Sanofi. She also served as a strategy consultant with the Monitor Consulting Group based in Hong Kong and the United States. Meeta holds a M.B.A. from the Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of Pennsylvania. She earned a bachelor’s degree in economics from the Shri Ram College of Commerce at Delhi University in India.

About Seer Inc.

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f74c338-98e5-4435-b55a-5e0a15dec7a4

FAQ

Who is Meeta Gulyani and what role has she taken at Seer?

Meeta Gulyani has been appointed to the Board of Directors at Seer, Inc., bringing vast experience from her role at Merck KGaA.

What experience does Meeta Gulyani have in the life sciences sector?

Gulyani has held key roles in strategy and business development in leading companies like Merck KGaA and Roche.

How might Meeta Gulyani's appointment affect Seer, Inc.?

Her expertise is anticipated to enhance Seer's strategic direction and support its mission in proteomics.

What is Seer, Inc. known for?

Seer, Inc. is known for its innovative Proteograph Product Suite, designed for advanced proteomic analysis.

What is the significance of Gulyani's global experience for Seer?

Gulyani's global experience, particularly in Asia, is crucial as Seer looks to expand its market reach in the life sciences sector.